Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials

Fig. 1

Change in HbA1c in patients with RA (irrespective of diabetes status) treated with a sarilumab 150/200 mg q2w + csDMARDs or placebo + csDMARDs and b sarilumab 200 mg q2w or adalimumab 40 mg q2w. Change in HbA1c in patients with RA and diabetes treated with c sarilumab 150/200 mg q2w + csDMARDs or placebo + csDMARDs and d sarilumab 200 mg q2w or adalimumab 40 mg q2w. p values are nominal. csDMARD, conventional disease-modifying antirheumatic drug; HbA1c, glycosylated haemoglobin; LS, least squares; PBO, placebo; q2w, every 2 weeks; RA, rheumatoid arthritis; SE, standard error

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us